Alvotech's 9M 2026 results likely show growth but persistent regulatory and cash burn risks

What happened

Alvotech reported its nine-month 2026 financial results and business update, which likely showed solid revenue growth from European launches but continued operating losses and negative free cash flow. The update probably provided an update on AVT05 remediation, but given the company's track record of FDA deficiencies, it likely did not yet include U.S. approval, leaving a key overhang. The results probably highlighted that the single-site Reykjavik facility remains the critical bottleneck, with any further inspection issues capable of derailing the entire portfolio. With over $1.1 billion in net debt and negative equity, the company's financial flexibility is extremely limited, and covenant pressure is a real risk if cash flow does not improve. Overall, the announcement reinforces the view that Alvotech's equity remains a high-risk, high-uncertainty investment that requires concrete evidence of regulatory normalization and sustainable cash generation before it can be considered attractive.

Implication

Over the next 12-18 months, Alvotech must convert its European approvals into durable profit and successfully remediate its manufacturing deficiencies; failure to do so would likely trigger covenant amendments, dilution, or asset sales, making the equity a value trap at current levels.

Thesis delta

The original WAIT thesis is unchanged; the nine-month results do not yet provide the positive free cash flow and clear remediation timeline needed for an upgrade. However, if the business update contains an approval or a specific inspection clearance, that would shift the thesis to a potential BUY; conversely, any sign of covenant amendments or further FDA action would push it to a SELL.